PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.
Vor Biopharma, a US-based developer of treatments for haematological malignancies, has filed for a $150m initial public offering that would allow pharmaceutical firms Johnson & Johnson, Novartis and PureTech Health to exit. Founded in 2015, Vor is working on drug treatments for haematological malignancies, a type of cancer that affects the blood, bone marrow and…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.